newsfilter
← Latest News
GlobeNewswire·

Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board

AKTX
  • Akari Therapeutics (NASDAQ: AKTX) appointed Dr. Olga Anczukow to its Scientific Advisory Board on Feb. 23, 2026.
  • Dr. Anczukow is an Associate Professor at The Jackson Laboratory for Genomic Medicine, a Co-Program Leader at the Jackson Laboratory Cancer Center, \& holds a joint faculty appointment at the University of Connecticut School of Medicine.
  • Her research focuses on alternative RNA splicing mechanisms in cancer, tumor initiation, progression, metastasis, \& therapeutic resistance.
  • Akari CEO Abizer Gaslightwala cited Dr. Anczukow's expertise in RNA splicing as critical for advancing the company's PH1 ADC payload.
  • The PH1 payload is a novel spliceosome modulator designed to disrupt RNA splicing in cancer cells, differing from traditional ADC payloads like tubulin inhibitors.
  • Lead candidate AKTX-101 targets the Trop2 receptor \& demonstrated significant activity, prolonged survival, \& potential synergy with checkpoint inhibitors in preclinical models.
  • AKTX-101 is also active against cancer cells with drivers such as KRAS, BRAF, ARV7, \& FGFR3 fusions.
  • The company has initiated IND-enabling studies for AKTX-101 with a goal to start First-In-Human trials by late 2026 or early 2027.
  • Akari is developing AKTX-102, an ADC candidate targeting the CEACAM5 antigen using the same PH1 payload platform.
  • The press release includes standard forward-looking statements regarding risks related to capital, regulatory approval, \& clinical trial outcomes.